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A B S T R A C T
Non-alcoholic steatohepatitis (NASH) is the leading cause of cirrhosis worldwide and the most rapidly growing
indication for liver transplantation. Macrophages are the important cellular component in the inﬂammatory
milieu in NASH. Inﬂammatory and pro-ﬁbrotic mediators produced by macrophages causes signiﬁcant tissue
injury in many inﬂammatory diseases. Therefore, inhibition of the inﬂammatory macrophages would be a
promising approach to attenuate NASH. In this study, we studied the implication of SYK pathway in NASH, and
investigated PLGA nanoparticles-based delivery of SYK pathway inhibitor as an eﬀective and promising ther-
apeutic approach for the treatment of NASH. We found positive correlation between SYK expression with the
pathogenesis of NASH and alcoholic hepatitis in patients. Importantly, SYK expression was signiﬁcantly induced
in M1-diﬀerentiated inﬂammatory macrophages. To inhibit SYK pathway speciﬁcally, we used a small-molecule
inhibitor R406 that blocks Fc-receptor signaling pathway and reduces immune complex-mediated inﬂammation.
R406 dose-dependently inhibited nitric-oxide release and M1-speciﬁc markers in M1-diﬀerentiated macro-
phages. Thereafter, we synthesized PLGA nanoparticles to deliver R406 to increase the drug pharmacokinetics
for the eﬃcient treatment of NASH. We investigated the therapeutic eﬃcacy of R406-PLGA in-vitro in diﬀer-
entiated macrophages, and in-vivo in Methionine-Choline-deﬁcient (MCD)-diet induced NASH mouse model.
R406-PLGA inhibited M1-speciﬁc diﬀerentiation markers in RAW and bone-marrow-derived macrophages. In-
vivo, R406 and more strongly R406-PLGA ameliorated ﬁbrosis, inﬂammation and steatosis in mice. R406 and
more signiﬁcantly R406-PLGA reduced ALT, AST, cholesterol and triglyceride plasma levels. These results
suggest that delivery of SYK inhibitor using PLGA nanoparticles can be a potential therapeutic approach for the
treatment of Non-alcoholic steatohepatitis.
1. Introduction
Cirrhosis and hepatocellular carcinoma (HCC) are the most common
liver-related causes of morbidity associated with NASH (Non-alcoholic
steatohepatitis) [1]. In the United States, NASH has already become the
second‑leading etiology of liver disease requiring liver transplantation
in adults [2–4]. Advanced ﬁbrosis or cirrhosis has been identiﬁed as the
most important histological feature associated with NASH [5]. Liver
ﬁbrosis is the condition characterized by excessive accumulation of
abnormal extracellular matrix (ECM) proteins, which results from
chronic non-resolving inﬂammation [6,7]. The inﬂammation triggers
the tissue destruction which further leads to scar tissue formation. Cell
death and inﬂammation represent two characteristic but intricately
linked features of the chronic liver disease that promote the
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development of ﬁbrosis [6,7].
Hepatic injury initiates a cascade of a ﬁbrogenic process initiated by
inﬂammatory and ﬁbrogenic signals. The activation process is initiated
by the release of growth factors, proﬁbrogenic cytokines and chemo-
kines by the injured hepatocytes, and inﬂammatory cells particularly
macrophages and other non-parenchymal cells [6–8]. Hepatic macro-
phages arise from circulating bone-marrow-derived monocytes, which
are recruited to the injured liver or from proliferating resident macro-
phages (Kupﬀer cells). Resident macrophages have shown to play a
signiﬁcant role in initiaton of the inﬂammatory responses during tissue
injury, while inﬁltrating monocyte-derived macrophages leads to
chronic liver inﬂammation and ﬁbrogenesis [7]. During enhanced re-
cruitment owing to liver damage and environmental cues, inﬁltrating
monocytes undergo diﬀerentiation into two broad subsets of macro-
phages that are categorized as classically-activated (M1) or alter-
natively-activated (M2). The initial inﬂammatory response is pre-
dominantly mediated by classically-activated (M1-diﬀerentiated)
macrophages (activated by Th1 cytokines e.g. IFN-γ and LPS). In con-
trast, the resolution phase of inﬂammation is driven by alternatively-
activated (M2-diﬀerentiated) macrophages, stimulated by Th2 cyto-
kines (IL-4 or IL-13) [7].
We have earlier demonstrated crucial role of signaling pathways in
liver ﬁbrogenesis [9–11]. Another major signaling pathway involved in
the pathogenesis of liver disease is Spleen tyrosine kinase (SYK) sig-
naling pathway [12–15]. SYK is a cytoplasmic tyrosine kinase of 72 KDa
that belongs to ZAP70/SYK family of the non-receptor protein tyrosine
kinases (PTKs) [16]. SYK was identiﬁed and known to be expressed in
hematopoietic cells, including macrophages, and has shown to be im-
portant in the downstream signaling events that drive inﬂammatory
pathways of both the innate and adaptive immune systems [16]. While
most studies focused on hematopoietic cells, SYK has also been shown
to be expressed in non-hematopoietic cells including ﬁbroblasts and
hepatocytes [15,17]. A recent study has reported the up-regulation of
SYK in hepatocytes and activated HSCs during liver ﬁbrosis that pro-
motes HSCs activation and proliferation via crosstalk between cytokines
secreted by hepatocytes and HSCs [15]. Many studies have also de-
monstrated the role of SYK in various inﬂammatory and ﬁbrotic dis-
eases, such as Rheumatoid Arthritis [18,19], allergic asthma/rhinitis
[20,21], renal interstitial ﬁbrosis [22] and that SYK inhibition could be
a therapeutic strategy for the treatment of inﬂammation- and ﬁbrosis-
related diseases [15,16,18,20,22]. SYK functions via an immuno-re-
ceptor tyrosine-based activation motif (ITAM) or Toll-like receptors
(TLRs) which are activated by pathogen-associated molecular patterns
(PAMP) [16,23]. Selective SYK inhibition or deletion in macrophages
has shown to reduce macrophage activation as shown by reduced
production of FcγR (Fc gamma receptor), CCL2 (or MCP1, macrophage
chemotactic protein 1), IL-6 and TNF-α (Tumor necrosis factor alpha)
[16,23]. Therapeutic inhibition of SYK has shown to ameliorate in-
ﬂammation and steatosis in Alcoholic liver diseases [12,13], and sup-
pressed liver ﬁbrosis via inhibition of HSC activation in animal models
[15]. However, implication and inhibition of SYK pathway in NASH
and speciﬁcally in M1 inﬂammatory macrophages has not been in-
vestigated yet.
Macrophages and especially the liver-resident Kupﬀer cells are in
the focus of nanomedicine due to their highly eﬃcient and non-speciﬁc
uptake of many nanomaterials as well as due to their critical pathogenic
functions during inﬂammation and ﬁbrogenesis [24]. One of the na-
noparticles is Poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles
that are widely used as drug delivery carriers in various biomedical
applications such as vaccination, cancer, inﬂammation, and other dis-
eases [25,26]. PLGA is a FDA-approved biodegradable polymer with
favorable mechanical properties, biodegradation kinetics, drug com-
patibility and biocompatibility since PLGA is biologically hydrolyzed to
metabolite monomers, lactic acid and glycolic acid [25]. These two
monomers are endogenously metabolized by the body via the Krebs
cycle therefore no systemic toxicity is associated with the utilization of
PLGA for drug delivery. PLGA-nanoparticles are internalized in cells
partly through ﬂuid-phase pinocytosis and through Clathrin-mediated
endocytosis [27].
In this study, we have analyzed the SYK expression in NASH and
alcoholic hepatitis (AH) patients. We have further examined the ex-
pression and activation of SYK signaling pathway in inﬂammatory
macrophages. We thereafter, using small-molecule SYK inhibitor R406,
studied the implication of therapeutic SYK inhibition in inﬂammatory
macrophages. For the eﬃcient delivery of SYK inhibitor R406 in vivo,
we synthesized R406-encapsulated PLGA nanoparticles and in-
vestigated their therapeutic eﬃcacy in vitro in M1-diﬀerentiated RAW
macrophages and murine bone marrow derived macrophages, and in
vivo in MCD diet-induced NASH mouse model.
2. Materials and methods
2.1. Cell lines
Murine RAW 264.7 macrophages were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA). RAW macro-
phages were cultured in Roswell Park Memorial Institute (RPMI) 1640
medium (Lonza, Verviers, Belgium) supplemented with 2mM L-gluta-
mine (Sigma, St. Louis, MO), 10% fetal bovine plasma (FBS, Lonza) and
antibiotics (50 U/mL Penicillin and 50 μg/mL streptomycin, Sigma).
2.2. Bone marrow derived macrophages
Bone marrow-derived macrophage (BMDM) cultures were freshly
isolated from C57BL/6 mice as described previously elsewhere [28].
Brieﬂy, femurs and tibias were ﬂushed with Dulbecco's modiﬁed Eagle's
medium (DMEM) (Life Technologies, Carlsbad, CA, USA) with 10% FBS
(Lonza) to collect bone marrow. Cells were then triturated 3–5 times
through an 18-gauge needle and centrifuged at 1200rpm for 5min.
After removing supernatant, RBCs were lysed with the lysis buﬀer and
the remaining cells were washed in DMEM +10% FBS and plated at
1× 106 cells/mL in DMEM supplemented with 1% penicillin/strepto-
mycin, 1% HEPES, 0.001% β-mercaptoethanol, 10% FBS, and 20%
supernatant from mouse 3T3 ﬁbroblasts [obtained from ATCC and
cultured in cultured in (DMEM) medium supplemented with 2mM L-
glutamine (Sigma), 10% FBS (Lonza) and antibiotics (Sigma)]. The ﬁ-
broblasts conditioned medium is required to promote diﬀerentiation of
bone marrow cells into macrophages (7–10 days). Media was changed
on days 2, 4, and 6, and cells were re-plated on day 7 for performing
experiments.
2.3. PLGA nanoparticles preparation
Poly (D,L-lactide-co-glycolide) (PLGA) nanoparticles were prepared
by the emulsiﬁcation solvent evaporation method as described earlier
[29]. Brieﬂy, the internal phase containing 100 μL ethyl acetate con-
taining 2.5mg PLGA [Poly (D,L-lactide-co-glycolide, with a co-
monomer ratio of 50/50 (lactic/glycolic acid), Mw=17,000, Corbion
Purac, Gorinchem, The Netherlands] and 40 μg R406 (Mw=628.63,
Selleckchem, Boston, NY) was emulsiﬁed into an external aqueous
phase of 100 μL of 2% Poly (vinyl-alcohol) (PVA, Sigma) (w/v), drop by
drop under constant vortexing at maximum speed. The formed o/w
microemulsion was subsequently sonicated for 2min at 5% power
output. The emulsion was transferred into 40mL of 0.3% PVA (w/v)
under magnetic stirring, and stirred overnight at room temperature to
evaporate organic solvent ethyl acetate and to solidify the emulsiﬁed
nanodroplets. The formed nanoparticles were isolated by centrifugation
for 60min at 16,000 rpm (rotor SS-34, Sorvall RC-5C Plus, Kendro Lab,
USA) and the supernatant was discarded. The resulting nanoparticles
were characterized for their average size and size distribution by dy-
namic light scattering (DLS) and zeta potential measurements using a
Nano ZS Zetasizer (Malvern Instruments Ltd., Malvern, UK). R406-
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PLGA nanoparticles were characterized using Scanning electron mi-
croscope (JEOL JSM-IT 100, Akishima, Japan) with a secondary elec-
tron detector and an acceleration voltage of 3–5 kV. The nanoparticle
dispersions were freeze-dried before-hand and mounted on conductive
carbon tape.
2.3.1. Determination of R406 encapsulation
R406 drug encapsulation (% DE) was done by developed HPLC
method using UPLC (Thermoscientiﬁc™ Dionex™ Ultimate™ 3000
system). Brieﬂy, 50 μL samples R406-PLGA in suspension were cen-
trifuged using MicroCL 17 centrifuge (Thermoscientiﬁc) for 5min at
13,300 rpm. Filtrates were discarded and the pellet was dissolved in
DMSO and measured with UPLC at λmax 261 nm (Fig. S1A). Diﬀerent
drug concentrations were used, and measured with UPLC and plotted as
a standard curve (Fig. S1B) for determination of drug concentration.
2.3.2. In vitro drug release and uptake by RAW macrophages
To perform the drug release study of R406 and R406-PLGA, we
plated the RAW cells (5× 105 cells/well) in 12 well plates and cultured
overnight. Then we added R406 and R406-PLGA in the cells.
Furthermore, 100 μL of samples were collected and replaced by an
equal volume of the medium at time intervals (0, 6, 12, 24, and 48 h).
The amount of drug released into the medium was calculated according
to a standard curve of R406 which is measured with UPLC. Each ex-
periment was conducted as three independent experiment (n=3). We
also performed the drug release study of R406 and R406-PLGA without
RAW cells, i.e. in the complete medium for RAW cells. The drug and the
nanoparticles with the medium incubated in a shaking incubator at
37 °C. The rest of the procedure was same as drug release study with
RAW cells. The drug uptake was measured as % total drug (at diﬀerent
time points) - % total drug left in the medium (at diﬀerent time points).
The graphs were ploted as % cumulative drug release (to depict drug
release) and % total drug uptake (to depict drug uptake by RAW
macrophages).
2.4. In vitro eﬃcacy studies in RAW cell macrophages
For diﬀerentiation of RAW macrophages, cells were plated (1×106
cells/well) in 12 well plates and cultured overnight. The cells were then
incubated with LPS (100 ng/mL, Sigma) and IFNγ (10 ng/mL,
Peprotech, Rocky Hill, NJ) for M1 diﬀerentiation, and IL-4 (10 ng/mL,
Peprotech) and IL-13 (10 ng/mL, Peprotech) for M2 diﬀerentiation for
24 h. To study the eﬀect of SYK inhibitor; RAW cells were incubated
with medium alone, 0.5, 1.0 and 5.0 μM of SYK inhibitor R406
(Selleckchem, Boston, NY) together with M1 diﬀerentiation stimulus for
48 h. For the eﬀect of SYK inhibitor R406 loaded nanoparticles (R406-
PLGA), M1-diﬀerentiated macrophages were incubated either with
5 μM R406, R406-PLGA (equivalent dose, 5 μM) or PLGA (empty na-
noparticles, equimolar concentration as R406-PLGA) for 48 h. Cells
were then lysed either with protein lysis buﬀer for western blot analysis
or RNA lysis buﬀer for quantitative real-time PCR analysis. All the ef-
ﬁcacy studies were performed at least 3 times independently.
2.5. In vitro eﬃcacy studies in freshly isolated murine bone marrow derived
macrophages
Bone marrow derived macrophages were plated at a density of
1× 106/mL and diﬀerentiated into M1 macrophages using LPS
(100ng/mL; sigma) and IFNγ (10ng/mL, Peprotech), or M2 macro-
phages using IL-4 (10ng/mL, Peprotech) and IL-13 (10 ng/mL,
Peprotech). For eﬃcacy studies, cells were incubated with medium
alone, SYK-loaded nanoparticles (R406-PLGA), empty nanoparticles
(PLGA) and free drug (R406) together with M1 stimulus. After 48 h of
incubation, cells were lysed for RNA isolation and real-time PCR ana-
lysis. Three independent experiments were performed.
2.6. Nitric oxide (NO) release bioassay
The eﬀect of R406 on M1 macrophages was assessed by measuring
the inhibition of nitric oxide (NO) release as described earlier [30], a
stable NO metabolite produced by M1 macrophages. RAW cells
(2× 105 cells/200 μL/well) were seeded in 96-well plates, were cul-
tured overnight and incubated with IFNγ (10 ng/mL, Peprotech) and
LPS (100 ng/mL, Sigma) together with diﬀerent concentrations of SYK
inhibitor R406 (0, 0.5, 1.0, and 5.0 μM). After 48 h, 100 μL culture
supernatant was added to 100 μL of Griess reagent (1% sulfanilamide
(Sigma), 0.1% naphthyl ethylenediamine dihydrochloride (Sigma); 3%
phosphoric acid (Sigma)) and the absorbance at 540 nm was measured
with a microplate reader. NO release assays were performed in tripli-
cates in three independent experiments.
2.7. Cell viability assay
To assess the eﬀects on cell viability, cells were plated in 96 well
plates, cultured overnight and incubated with diﬀerent concentrations
of R406 (0.1, 0.5, 1.0, and 5.0 uM) together with M1 stimulus (100 ng/
mL LPS and 10 ng/mL IFNγ) for 48 h. To study the eﬀects of R406-PLGA
on cell viability, cells were incubated with R406-PLGA (equivalent
dose, 5 μM), PLGA (empty nanoparticles, equimolar concentration as
R406-PLGA) or free drug R406 (5 μM) together with M1 stimulus for
48 h. Cell viability assays were performed using Alamar Blue reagent
(Invitrogen, Carlsbad, CA, USA) as per manufacturer's instructions. The
results are represented as % cell viability normalized to untreated
control cells (at 100%). All measurements were performed in triplicates
in three independent experiments.
2.8. Methionine and choline-deﬁcient (MCD) diet model
Animal studies were conducted in strict accordance with the
guidelines and ethical regulations for the Care and Use of Laboratory
Animals, CSIR-Central Drug Research Institute, India. The protocols
were approved by the Institutional Animal Ethics Committee at the
CSIR-Central Drug Research Institute, India. 8-week old male C57BL/6
mice (Jackson Laboratories, Bar Harbor, USA) were fed on MCD diet
(C1070, Altromin GmbH, Lage, Germany) for 4 weeks while the con-
trols received regular chow diet (n=4) for 4weeks. In this study, we
used male mice since it has been shown that male mice develop more
severe fatty liver disease as compared to female mice. Furthermore,
male mice were shown to be more vulnerable to hepatic lipid accu-
mulation while on MCD diet as compared to female mice. This study
also suggested the reduction of fatty liver disease development in fe-
male mice due to the sex hormones e.g. estrogen [31]. MCD male mice
were treated for two weeks intravenously (three times per week) with
vehicle (PBS, n=5), R406 (10mg/kg, n=5), R406-PLGA (equivalent
dose of 10mg/kg, n=5) or PLGA (empty nanoparticles, equimolar
concentrations as R406-PLGA, n=5) while continuing MCD diet (Fig.
S2) At the end of the experiment, mice were euthanised and the liver
tissues and blood samples were collected for analysis. Alanine amino-
transferase (ALT), aspartate aminotransferase (AST), total plasma cho-
lesterol levels and plasma triglycerides levels were measured by stan-
dard automated laboratory methods.
2.9. RNA extraction, reverse transcription, quantitative real-time PCR
Total RNA from cells and liver tissues was isolated using GenElute
Total RNA Miniprep Kit (Sigma) and SV total RNA isolation system
(Promega Corporation, Madison, WI, USA), respectively, according to
manufacturer's instructions. The RNA concentration was quantitated by
a UV spectrophotometer (NanoDrop Technologies, Wilmington, DE).
Total RNA (1 μg) was reverse-transcribed using iScript cDNA Synthesis
Kit (Bio-Rad, Hercules, CA). All the primers were purchased from
Sigma-Genoysis (Haverhill, UK). Real-time PCR was performed using
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2× SensiMix SYBR and Fluorescein Kit (Bioline, QT615–05,
Luckenwalde, Germany), 20 ng cDNA and pre-tested gene-speciﬁc
primer sets. The cycling conditions for the BioRad CFX384 Real-Time
PCR detection system were 95 °C for 10min, 40 cycles of 95 °C/15 s,
72 °C/15 s, and 58 °C/15 s. Finally, cycle threshold (Ct) values were
normalized to reference gene 18 s rRNA and fold changes in expression
were calculated using the 2-ΔΔCt method. All primers were purchased
from Sigma-Genosys (Haverhill, UK). The primer sequences are given in
Table S1.
2.10. Western blot analysis
Cells were lysed using 1× Cell Lysis Buﬀer containing 1× DTT
reducing agent (Cell Signaling Technology, Leiden, the Netherlands)
and homogenized using ultra-sonication on ice. The samples were
boiled and subjected to SDS-PAGE with 10% Tris-glycine gels (Life
Technologies) followed by protein transfer onto PVDF membrane. The
membranes were developed according to the standard protocols using
primary and secondary antibodies (as mentioned in Table S2). The
bands were developed using ECL detection reagent (Perkin Elmer Inc.,
Walthan, MA) and photographed using FluorChem M Imaging System
(ProteinSimple, Alpha Innotech, San Leandro CA). Intensity of in-
dividual bands were quantiﬁed using NIH ImageJ densitometry soft-




Liver tissues were harvested and transferred to Tissue-Tek OCT
embedding medium (Sakura Finetek, Torrance, CA) and snap-frozen in
2-methyl butane chilled in a dry ice. Cryosections (6 μm) were cut using
a Leica CM 3050 cryostat (Leica Microsystems, Nussloch, Germany).
The sections were air-dried and ﬁxed with acetone for 20min. Tissue
sections were rehydrated with PBS and incubated with the primary
antibody for overnight at 4 °C. Sections then were incubated with
horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h at
room temperature. Then incubated with HRP-conjugated tertiary anti-
body for 1 h at room temperature. Afterwards, peroxidase activity was
developed using AEC (3-amino-9-ethyl carbazole) substrate kit (Life
Technologies, Carlsbad, CA) for 20min and nuclei were counterstained
with hematoxylin (Fluka Chemie, Buchs, Switzerland). Endogenous
peroxidase activity was blocked by 3% H2O2 prepared in methanol. The
sections were mounted with Aquatex mounting medium (Merck,
Darmstadt, Germany) and were scanned using Hamamatsu
NanoZoomer Digital slide scanner 2.0HT (Hamamatsu Photonics,
Bridgewater, NJ). The details about the antibodies used for im-
munostainings are provided in Table S2.
2.11.2. Oil-Red-O staining
Oil-Red-O stock solution was prepared by dissolving 0.3 g Oil-Red-O
(Sigma) in 100mL isopropanol. Sections were ﬁxed in 4% formalin for
20min and were then stained in Oil-Red-O solution as per manufac-
turer's instructions. Brieﬂy, formalin-ﬁxed sections were rinsed with
60% isopropanol followed by staining with freshly prepared Oil Red O
working solution for 15min. Thereafter, sections were rinsed with 60%
isopropanol and nuclei were counterstained with hematoxylin (Fluka
Chemie). Finally, sections were rinsed with tap water and were
mounted with aquatex mounting medium (Merck).
2.11.3. Hematoxylin and Eosin staining
Sections were ﬁxed with 4% formalin for 20min and then rinsed
with distilled water. The sections were incubated with hematoxylin for
15min followed by washings with tap water. Thereafter, sections were
incubated with eosin solution for 1.5min followed by wash in 96%
ethanol, dehydration with ethanol and were mounted with VectaMount
mounting medium (Vector Laboratories, Burlingame, CA).
2.11.4. Quantitative histological analysis
For quantitation, stained sections were scanned at high resolution
using Hamamatsu NanoZoomer Digital slide scanner 2.0HT
(Hamamatsu Photonics). High resolution scans were viewed using
NanoZoomer Digital Pathology (NDP2.0) viewer software (Hamamatsu
Photonics). About 20 images (100×) of each entire section (from NDP)
were imported into ImageJ software and were analyzed quantitatively
at a ﬁxed threshold.
2.12. SYK gene expression in the human liver tissues
SYK mRNA expression was assessed in the publicly available tran-
scriptome datasets of liver tissue from patients with NASH (GSE48452)
[32] obtained from the National Center for Biotechnology Information
Gene Expression Omnibus database (GEO). Patients were categorized
into 4 groups as per biopsy-based pathological investigation: control
group (n=23); NAFLD activity score NAS 1–2 (n=13); NAS 3–4
(n=7) and NAS 5–6 (n=15).
High-throughput transcriptome proﬁling was performed using
Illumina HiSeq2000 platform (San Diego, CA) with liver samples pro-
vided by the InTeam Consortium (Human Biorepository Core,
University of Pittsburgh, PA) as described recently [18]. SYK mRNA
expression was evaluated in patients with diﬀerent phenotypes: 11
patients with non-severe alcoholic hepatitis (with Maddrey's dis-
criminant function, MDF ≤32); AH responders (with severe alcoholic
hepatitis (MDF > 32) patients responsive to steroids, n=9) AH non-
responders (AH severe alcoholic hepatitis (MDF > 32) patients non-
responsive to steroids therapy, n=9) and 10 patients with explants
who underwent early liver transplantation for severe alcoholic hepa-
titis. Controls (n=10) were non-diseased livers obtained from biopsied
single nodules, whose histology was without signiﬁcant alterations.
2.13. Statistical analyses
All the data are presented as a mean+ standard error of the mean
(SEM). The graphs and statistical analyses were performed using
GraphPad Prism version 5.02 (GraphPad Prism Software, Inc., La Jolla,
CA). Comparison to control group were analyzed using unpaired stu-
dents' t-test while multiple comparisons between diﬀerent groups were
performed by one-way analysis of variance (ANOVA) with Bonferroni
post-hoc test. The diﬀerences were considered signiﬁcant at p < .05.
3. Results and discussion
3.1. Upregulation of SYK expression in NASH and AH patients, and
inﬂammatory macrophages
Previous studies have documented that the functional inhibition of
SYK pathway attenuates the severity of inﬂammatory diseases and ﬁ-
brotic diseases [12,13,15,16]. In this study, we investigated the asso-
ciation of SYK expression with pathogenesis of NASH (non-alcoholic
steatohepatitis) and AH (Alcoholic hepatitis). Using transcriptome
analysis, we found a highly signiﬁcant induction of SYK expression that
correlated with the increasing NAS score (NAFLD activity score) as
compared to normal livers (GEO accession number: GSE48452)
(Fig. 1A). In AH patients, we found a signiﬁcant correlation between
AH severity and SYK expression (Fig. 1B) with increasing SYK expres-
sion from healthy individuals to AH non-severe, AH responders (AH
patients responsive to steroids), AH non-responders (AH patients non-
responsive to steroids therapy) and AH explants (AH severe patients
with early liver transplantation). Likewise, previous studies have shown
correlation of SYK and SYK pathway activation in liver ﬁbrosis and
alcoholic liver disease (ALD) patients as compared to healthy controls
[13,15]. Since macrophages are the key pathogenic cells in NASH and
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inﬂammatory liver diseases [33], we analyzed the SYK expression in
diﬀerentiated murine RAW macrophages i.e. LPS- and IFNγ-induced
M1-diﬀerentiated inﬂammatory macrophages, and IL-4- and IL-13-in-
duced M2-diﬀerentiated restorative macrophages. We ﬁrst conﬁrmed
the diﬀerentiation of macrophages using M1 and M2-speciﬁc markers
and found that M1-diﬀerentiated macrophages signiﬁcantly expressed
M1 markers i.e. iNOS (inducible nitric oxide synthase or NOS2), IL-1β
(Interleukin-1-beta), CCL2 [chemokine (C—C motif) ligand 2 or MCP1,
monocyte chemoattractant protein 1] and IL-6 (Interleukin-6) while
M2-diﬀerentiated macrophages expressed M2 markers i.e. MRC1
(mannose receptor complex 1) and ARG (Arginase I) (Fig. 1C). We then
analyzed SYK expression in these diﬀerently diﬀerentiated macro-
phages. We observed signiﬁcant upregulation of SYK mRNA and protein
expression in LPS- and IFNγ-diﬀerentiated M1 inﬂammatory macro-
phages as compared to undiﬀerentiated macrophages, and IL-4 and IL-
13-mediated M2-diﬀerentiated restorative macrophages (Fig. 1D,E).
These results suggest SYK as an appropriate molecular target in mac-
rophages and inﬂammatory liver diseases especially NASH.
3.2. SYK inhibitor R406 inhibited LPS- and IFNγ-induced SYK activation in
murine RAW macrophages
Since SYK expression was upregulated in M1-diﬀerentiated in-
ﬂammatory macrophages, we explored the implication of this receptor
in macrophages. We used R406 which is a potent SYK inhibitor
(Fig. 2A), to inhibit SYK signaling pathway, that has been used earlier
[13]. We ﬁrst examined the phosphorylation of SYK and observed that
increased SYK expression in M1 macrophages was accompanied with
increased phosphorylation of SYK (Fig. 2B,C). We then tested the eﬀect
of R406 on SYK phosphorylation and functional activation i.e. nitric
oxide (NO) release in M1-diﬀerentiated macrophages. We found that
R406 concentration dependently reduced SYK phosphorylation i.e. SYK
signaling pathway (Fig. 2B,C) and LPS- and IFNγ-induced NO release
(Fig. 2D). In addition, we performed viability studies and found no
toxicity with R406 (Fig. S3).
3.3. SYK inhibitor R406 inhibited gene expression of inﬂammatory markers
in mouse RAW macrophages
We further examined the eﬃcacy of R406 on gene expression of
inﬂammatory markers in M1-diﬀerentiated macrophages. We observed
that R406 concentration dependently inhibited LPS- and IFNγ-induced
gene expression of M1 markers i.e. IL1β, Fc gamma receptor 1 (FcγR1),
iNOS, CCL2 (or MCP1), IL-6 and CCR2 (C—C motif chemokine receptor
2) (Fig. 3A-F). These results are consistent with previous studies in
experimental animal models [13,34,35]. Altogether, these results sug-
gest that SYK inhibitor R406 treatment can potentially inhibit in-
ﬂammatory macrophages and hence R406 has high potency for the
treatment of inﬂammation-associated diseases. Inﬂammation in the
liver protects this organ from infection and injury, but excessive in-
ﬂammation may lead to extensive loss of hepatocytes, ischemia-re-
perfusion injury, metabolic alterations, and eventually hepatic damage.
Therefore, inhibition of inﬂammation or inﬂammatory macrophages
via SYK pathway inhibition might be promising approach for the
treatment of inﬂammatory liver diseases.
3.4. Preparation and characterization of R406-PLGA nanoparticles
Since small-molecule tyrosine kinase inhibitors have been shown to
have poor pharmacokinetics and bioavailability [36], we prepared
R406-encapsulated PLGA nanoparticles (R406-PLGA, Fig. 4A) to im-
prove the pharmacokinetics and thereof in vivo therapeutic eﬃcacy of
R406. R406-PLGA nanoparticles (R406-PLGA) were analyzed for the
morphology, size and zeta potential (Fig. 4B,C). R406-PLGA has Z-
average 159.7 nm, with almost comparable size to the control empty
PLGA nanoparticles (PLGA) (Fig. 4C). The zeta potential was towards
negative as shown in Fig. 4C. We also measured the drug encapsulation
of R406 in the PLGA nanoparticles using HPLC (Fig. S1A,B). The drug
encapsulation of R406 in the PLGA nanoparticles was found to be
37.49%. We further examined the physical stability of the R406-PLGA
nanoparticles and observed that the particle size remained relatively
stable at around 160 nm size after 46 days. These results suggest the
Fig. 1. Upregulation of SYK expression in NASH and AH patients, and diﬀer-
entiated macrophages. (A) Normalized SYK mRNA expression in the liver tis-
sues from NASH patients: Control (n=23); NAFLD activity score (NAS) 1–2
(n=13); NAS 3–4 (n=7); NAS 5–6 (n=15). (B) Normalized SYK mRNA ex-
pression in the alcoholic hepatitis (AH) patients: controls (non-diseased livers,
n=10); AH non-severe (n=11 patients); AH responders (AH patients re-
sponsive to steroids, n=9); AH non-responders (AH patients non-responsive to
steroids therapy, n=9) and AH explants (AH severe patients with early liver
transplantation, n= 11). (C) Gene expression of macrophage diﬀerentiation
markers: iNOS, IL-1β, CCL2, IL-6 (M1 macrophages); MRC1 and ARG1 (M2
macrophages). Expression values for the respective genes in control M0 mac-
rophages were set at 1.0 to calculate the relative gene expression in M1 and M2
macrophages. (D) SYK gene expression in the undiﬀerentiated macrophage
(control), M1 and M2 macrophages. (E) SYK protein expression as compared to
β-actin and the respective quantitative analysis. Data are presented as
mean ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001 denotes sig-
niﬁcance.
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successful synthesis of R406-PLGA nanoparticles with favorable particle
size and stability for appropriate delivery of SYK inhibitor.
3.5. R406-PLGA nanoparticles inhibited the SYK signaling pathway and
gene expression of inﬂammatory markers in RAW macrophages
Following successful synthesis of R406-PLGA nanoparticles, we ex-
amined the R406 eﬃcacy after encapsulation in PLGA nanoparticles.
Fig. 2. Inhibition of SYK phosphorylation and nitric
oxide release by SYK inhibitor R406 in RAW mac-
rophages. (A) Structure of R406, a SYK inhibitor. (B)
Protein expression and (C) quantitative densitometry
analysis of phosphorylated SYK (pSYK) as compared
to SYK in RAW 264.7 macrophages after incubation
with medium alone, M2 stimulus (10 ng/mL IL-4 and
10 ng/mL IL-13) and M1 stimulus (100 ng/mL
LPS+10 ng/mL IFNγ) without and with R406 (0,
0.5, 1 and 5 μM). (D) Nitric oxide (NO) release as
measured in the culture supernatant of RAW 264.7
cells incubated with medium alone (M0 or control)
or M1 stimulus (100 ng/mL LPS+ 10 ng/mL IFNγ)
with R406 (0, 0.5, 1 and 5 μM). Data are presented as
mean+ SEM. #p < 0.05, ##p < 0.01 denotes
signiﬁcance versus control M0 undiﬀerentiated
macrophages. *p < 0.05, **p < 0.01 and
***p < 0.001 denotes signiﬁcance versus M1-dif-
ferentiated macrophages.
Fig. 3. Inhibition of M1-speciﬁc diﬀerentiation and inﬂammatory markers by R406 in RAW macrophages. Gene expression of M1 markers IL-1β (A); FcγR1 (B); iNOS
(C); CCL2 (D); IL-6 (E); and CCR2 (F) in RAW 264.7 cells after incubation with medium alone (M0) or M1 stimulus with R406 (0, 0.5, 1, and 5 µM). Expression values
for the respective genes in untreated M1 macrophages were set at 1.0 to calculate the relative gene expression. Data are presented as mean + SEM. #p < 0.05,
##p < 0.01 denotes signiﬁcance versus control M0 macrophages.*p < 0.05, **p < 0.01 and ***p < 0.001 denotes signiﬁcance versus M1-diﬀerentiated mac-
rophages.
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We ﬁrst tested R406-PLGA nanoparticles in RAW macrophages for in-
hibition of SYK pathway and we found that both R406 and R406-PLGA
nanoparticles signiﬁcantly inhibited the SYK signaling pathway (SYK
phosphorylation) as shown in Fig. 4E,F. While empty PLGA
nanoparticles alone didn't show any eﬀect in SYK phosphorylation
(Fig. 4E,F). We further investigated the therapeutic eﬀects of R406-
PLGA nanoparticles in M1-diﬀerentiated inﬂammatory macrophages.
Interestingly, both R406 and R406-PLGA nanoparticles signiﬁcantly
Fig. 4. Characterization of R406-PLGA nanoparticles: (A) Representative Image of R406-PLGA nanoparticles as characterized by scanning electron microscope
(SEM); (B) Schematic representation depicting the drug (R406) encapsulated in the PLGA nanoparticles; (C) The average particle size, polydispersity index (PDI), and
zeta potential (ZP) of R406-PLGA NPs (or R406-PLGA) as compared to empty-NPs (PLGA); (D) Physical stability (size stability) of R406-PLGA NPs for 46 days. (E)
Protein expression and (F) quantitative densitometry analysis of pSYK compared to SYK on RAW 264.7 cells after incubation with medium alone (control), M2
stimulus (10 ng/mL IL-4 and 10 ng/mL IL-13), M1 stimulus (100 ng/mL LPS+10 ng/mL IFNγ) with or without R406 (free drug), R406-PLGA or empty-NPs (PLGA).
Data are presented as mean+SEM. *p < 0.05 and **p < 0.01 denotes signiﬁcance.
Fig. 5. Inhibition of inﬂammatory markers or M1 diﬀerentiation markers by R406 and R406-PLGA in RAW macrophages. Gene expression of inﬂammatory or M1-
diﬀerentiation macrophages markers in RAW 264.7 cells: (A) iNOS; (B) FcγR1; (C) IL-6; (D) IL-1β; (E) CCL2 and (F) IL-1α after incubation with medium alone (M0
undiﬀerentiated macrophages) or M1 stimulus (100 ng/mL LPS+ 10 ng/mL IFNγ) with or without R406 (free drug), R406-PLGA or empty-NPs (PLGA). Data are
presented as mean+SEM. #p < 0.05, ##p < 0.01 denotes signiﬁcance versus control M0 macrophages. *p < 0.05, **p < 0.01 and ***p < 0.001 denotes
signiﬁcance versus M1-diﬀerentiated macrophages.
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inhibited the gene expression of M1-speciﬁc markers i.e. iNOS, FcγR1,
IL-6, IL-1β, CCL2 and IL-1α (Fig. 5A-F). However, we observed R406
was more eﬀective than R406-PLGA nanoparticles which is probably
due to slow drug release kinetics of PLGA nanoparticles [25]. Generally,
higher content of polyglycolide leads to quicker rates of degradation
with an exception of 50:50 ratio of PLA/PGA which is used in this study
exhibits the fastest degradation. As per modeling studies, PLA/PGA
50:50 demonstrated release kinetics of about 2–3weeks to achieve
100% drug release [25]. Furthermore, studies have found, that the type
of drug also plays a critical role in determining the release kinetics [37].
We performed drug release studies using R406-PLGA nanoparticles and
found that % cumulative release of R406 from PLGA nanoparticles in-
creases gradually after incubation for 48 h as compared to the free drug
(Fig. S4A). Furthermore, we performed drug uptake studies and ob-
served that R406 (in free form) was signiﬁcantly taken up more in RAW
macrophages (about 54% at 48 h) as compared to R406 (from PLGA
nanoparticles) (about 45% at 48 h) as can be seen in Fig. S4B. These
data supports the reduced in vitro therapeutic eﬃcacy of R406-PLGA as
compared to free R406, however further suggest slow and gradual re-
lease of R406 which will be desired in vivo. Essentially, these results
also suggest that R406 retained its therapeutic eﬀects following en-
capsulation in PLGA nanoparticles. We also performed the cell viability
studies with R406-PLGA nanoparticles and observed no eﬀect on cell
viability as shown in Fig. S5.
3.6. R406-PLGA nanoparticles inhibited the SYK signaling pathway and
gene expression of inﬂammatory markers in murine bone marrow derived
macrophages
In general, immortalized cells are not considered normal as they
divide indeﬁnitely and express unique gene patterns that are not found
in cell type in vivo and hence they might not have the relevant attri-
butes of normal cells. Thus, it is important to validate the character-
istics and results on primary cells that have not been passaged many
times. To mimic the in vivo more closely, we performed studies on
primary murine bone marrow derived macrophages (BMDMs). We ﬁrst
investigated the expression of SYK in BMDMs and observed signiﬁcant
upregulation of SYK expression in M1-diﬀerentiated BMDMs as com-
pared to undiﬀerentiated and M2-diﬀerentiated BMDMs (Fig. 6A).
Thereafter, we examined the eﬀect of R406-PLGA nanoparticles on the
gene expression of inﬂammatory markers in M1-diﬀerentaited in-
ﬂammatory BMDMs. We found that both R406 and R406-PLGA nano-
particles induced highly signiﬁcant down-regulation in the expression
levels of major inﬂammatory markers i.e. CCL2, IL-1α and IL-6 as
shown in Fig. 6B-D. These results further conﬁrmed our previous results
in RAW macrophages and suggest that R406 retained its therapeutic
eﬃcacy after encapsulation in PLGA nanoparticles. Notably, we did not
observe any eﬀects from empty PLGA nanoparticles in RAW macro-
phages and in BMDMs (Fig. 5A-F, 6B-D).
3.7. R406-PLGA nanoparticles ameliorated liver inﬂammation, ﬁbrosis and
steatosis in MCD diet induced NASH mouse model
Finally, we investigated the therapeutic eﬃcacy of R406-PLGA na-
noparticles in MCD-diet induced NASH mouse model. We ﬁrst ex-
amined the expression of SYK expression in mice with MCD-diet in-
duced NASH and found that SYK expression was highly signiﬁcantly
induced in mice with NASH as compared to healthy controls. With this
observation, we surmised that SYK play a major role in MCD-diet in-
duced liver steatosis. We then examined the therapeutic eﬃcacy of
R406 and R406-PLGA nanoparticles in MCD-diet induced NASH. We
followed the clinical treatment regimen, where we induced NASH for
4 weeks and treated mice for last 2 weeks with in total 4 intravenous
administrations while continuing with MCD diet (Fig. S2).
Morphological examination of liver tissues at the end of the study
showed the visible pale and gross appearance suggesting the hepato-
cellular damage in MCD-diet induced NASH mice as compared to
normal healthy control group (Fig. 7B). Treatment with R406 and
R406-PLGA showed considerably better appearance of livers in contrast
to MCD-diet induced NASH livers and PLGA-treated NASH livers
Fig. 6. Inhibition of inﬂammatory markers or M1
diﬀerentiation markers by R406 and R406-PLGA in
murine bone marrow derived macrophages. (A)
Normalized SYK expression in undiﬀerentiated M0,
M1-diﬀerentiated and M2-diﬀerentiated macro-
phages. Gene expression of inﬂammatory markers:
(B) CCL2; (C) IL-1α and (D) IL-6 after incubation
with medium alone (undiﬀerentiated M0 macro-
phages) or M1 stimulus (100 ng/mL LPS+10 ng/mL
IFNγ) with or without R406 (free drug), R406-PLGA
or empty-NPs (PLGA). Data are presented as
mean+ SEM. #p < 0.05, ##p < 0.01 denotes
signiﬁcance versus control M0 macrophages.
*p < 0.05, **p < 0.01 and ***p < 0.001 denotes
signiﬁcance versus M1-diﬀerentiated macrophages.
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Fig. 7. R406-PLGA ameliorates inﬂammation, steatosis and ﬁbrosis in methionine and choline-deﬁcient (MCD) diet induced NASH mouse model. (A) Representative
images of liver tissue from control group (chow-fed mice, n=4), MCD group (MCD diet-fed mice, n=5), MCD+R406 group (MCD diet-fed mice treated with free
drug R406, n=5), MCD+R406-PLGA group (MCD diet-fed mice treated with R406-PLGA nanoparticles, n=5), and MCD+PLGA group (MCD diet-fed mice
treated with empty PLGA nanoparticles, n=5). (B) Normalized SYK expression in liver tissue from MCD diet NASH mice (n= 5) compared to control mice (n=5).
**p < .01 denotes signiﬁcance. (C) Representative images of liver sections stained with hematoxylin and eosin (H&E) staining, Oil-red-O staining, and Collagen I,
F4/80 and MHC II as performed on healthy controls and MCD diet mice treated with respective treatments. (D) Quantitative image analysis of liver sections from
healthy controls and MCD diet mice treated with respective treatments stained with Oil-red-O, collagen I, F4/80 and MHC II. Data are presented as mean+ SEM.
#p < 0.05 denotes signiﬁcance versus healthy controls; *p < 0.05, **p < 0.01, ***p < 0.001 denotes signiﬁcance versus MCD diet mice.
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(Fig. 7B). Interestingly, we found that SYK inhibitor R406 and more
signiﬁcantly R406-PLGA nanoparticles ameliorated (a) hepatic in-
ﬂammation as examined by H&E, F4/80 (macrophage marker) and
MHC-II staining's; (b) hepatic ﬁbrosis as conﬁrmed by collagen I (major
extracellular matrix protein) expression; and (c) hepatic steatosis as
examined using oil-red-o staining (Fig. 7C,D).
We further examined plasma liver transaminases i.e. ALT and AST
levels, and found that R406 and more eﬃciently R406-PLGA inhibited
MCD-diet induced AST and ALT levels (Fig. 8A,B). We also analyzed
intrahepatic expression of SYK pathway downstream signaling mole-
cule CARD9 (caspase recruitment domain-containing protein 9) [38,39]
and found highly signiﬁcant inhibition of CARD9 by R406-PLGA na-
noparticles as compared to R406 (Fig. 8C).
In in vitro studies, we observed that both R406 and R406-PLGA
nanoparticles decreased CCL2 (MCP1) expression in RAW macrophages
and BMDMs, which was further implicated in the in vivo studies.
Reduced intrahepatic CCL2 expression by R406 and R406-PLGA na-
noparticles inhibits the macrophage chemotaxis/migration to liver as
shown by F4/80 protein expression therefore further inhibiting ongoing
liver inﬂammation (Fig. 7C,D). Previous studies have demonstrated the
crucial role of CCL2 in liver inﬂammation and shown that pharmaco-
logical inhibition of CCL2 ameliorated liver inﬂammation by inhibition
of macrophage inﬁltration [28]. We also analyzed gene expression of
F4/80 and crucial inﬂammatory markers i.e. CCL2, TNFα, iNOS and
intracellular cell adhesion molecule 1 (ICAM1), and found that MCD-
diet induced the macrophage inﬂux (as shown by F4/80 expression)
and inﬂammatory markers which were inhibited by R406 and more
signiﬁcantly by R406-PLGA nanoparticles suggesting highly beneﬁcial
and superior eﬀects of R406-PLGA nanoparticles as compared to R406
alone (Fig. 8D-H).
As previously demonstrated by us, there is a cross-talk between
macrophages and hepatic stellate cells (HSCs, major ﬁbrogenic cells in
liver) [9,10], therefore reduced inﬂammation resulted in reduced liver
ﬁbrosis as conﬁrmed by collagen I expression. R406 and more strongly,
R406-PLGA nanoparticles inhibited collagen I expression (Fig. 7C,D).
We further analyzed the gene expression of HSCs speciﬁc markers i.e.
desmin and alpha smooth muscle actin (α-SMA). We observed that
R406 and more potently R406-PLGA nanoparticles signiﬁcantly in-
hibited expression of MCD-diet induced HSCs activation while empty
PLGA nanoparticles showed no inhibitory eﬀects (Fig. 9A,B). These
results collectively suggests that R406-PLGA nanoparticles signiﬁcantly
inhibited ﬁbrosis in MCD-diet induced NASH model.
Finally, we analyzed the eﬀect of R406-PLGA on hepatic steatosis.
Oil-Red-O staining showed signiﬁcant induction in hepatic steatosis in
MCD-induced NASH which was inhibited by R406 and more strongly by
R406-PLGA nanoparticles (Fig. 7C,D). We ﬁrst examined total plasma
cholesterol and triglyceride levels, and found signiﬁcant upregulation
of these parameters in NASH mice as compared to healthy controls.
Interestingly, MCD-diet-induced cholesterol and triglyceride levels
were highly signiﬁcantly inhibited by R406 and, more eﬃciently, by
R406-PLGA nanoparticles (Fig. 9C,D). Furthermore, we analyzed ex-
pression of steatosis related markers: UCP1 (uncoupling protein 1),
PDRM16 (PR-domain containing 16), PGC1α (Peroxisome proliferator-
activator receptor gamma coactivator 1 alpha) and c/EBPβ (CCAAT/
enhancing binding protein β). UCP1, PDRM16 and PGC1α has been
shown to induce lipid oxidation and hence are involved in PGC1α/
PDRM16/UCP1-mediated lipid energy dissipation [39]. c/EBPβ
(CCAAT/enhancing binding protein β), has shown to have a key role in
steatosis and the pathophysiology of MCD diet-mediated model of
NASH through its eﬀect on lipid synthesis, inﬂammation and ER stress
Fig. 8. Increased therapeutic eﬃcacy of R406-PLGA nanoparticles in methionine and choline-deﬁcient (MCD) diet induced NASH in mice. (A) Plasma Aspartate
aminotransferase (AST) levels and (B) Plasma Alanine aminotransferase (ALT) levels. Intrahepatic gene expression of (C) CARD9 (caspase recruitment domain-
containing 9); (D) macrophage marker F4/80; (E) monocyte chemoattractant protein 1 (MCP1) or chemokine (C—C motif) ligand 2 (CCL2); (F) inﬂammatory
cytokine, tumor necrosis factor alpha (TNF-α); (G) inducible nitric oxide synthase (iNOS or NOS2) and (H) intracellular cell adhesion molecule 1 (ICAM-1). Data are
presented as mean+SEM. *p < 0.05, **p < 0.01 denotes signiﬁcance.
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[40]. We found that R406-PLGA nanoparticles alone induced the ex-
pression of PGC1α, PDRM16, UCP1 and reduced MCD-diet induced C/
EBPβ expression suggesting increased lipid oxidation, reduced lipid
synthesis and reduced steatosis (Fig. 9E-H). Altogether, these results
suggest that R406 and more signiﬁcantly R406-PLGA nanoparticles
signiﬁcantly ameliorated ﬁbrosis, inﬂammation and steatosis in NASH
mouse model. Importantly, PLGA-mediated delivery signiﬁcantly in-
creased the in vivo therapeutic eﬃcacy of R406 and therefore poten-
tially reduce the frequency of drug administration.
4. Conclusion
In conclusion, we have demonstrated schematically a novel role of
SYK signaling pathway in modulating liver inﬂammation, ﬁbrosis and
steatosis attributed to non-alcoholic steatohepatitis. We have also
shown the role of SYK pathway in inﬂammatory M1 macrophages.
Furthermore, this study highlights SYK inhibitor R406 as a potential
therapeutic for NASH. Using PLGA nanoparticles, we have demon-
strated the eﬃcient intrahepatic delivery of SYK inhibitor for increased
therapeutic eﬃcacy as shown by decreased inﬂammation, hepatic in-
jury, ﬁbrosis and steatosis by suppressing c/EBPβ-mediated lipogenesis
and increased PGC1α/PDRM16/UCP1-mediated lipid energy dissipa-
tion. To our best knowledge, this is the ﬁrst study highlighting the in-
creased therapeutic eﬀects of SYK inhibitor using PLGA-mediated de-
livery in NASH. This promising strategy can potentially be applicable
for the treatment of other inﬂammatory diseases and should be further
explored for the systematic evaluation for the clinical applications.
Acknowledgements
This study was funded by Endowment Fund for the Education
Republic of Indonesia (Lembaga Pengelola Dana Pendidikan/LPDP RI).
This project was partially supported by the Netherlands Organization
for Health Research and Development (ZonMW, NWO)-funded VENI
innovation grant 916.151.94 (to R.B.). Authors thank Hetty ten Hoopen
for her technical assistance.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jconrel.2018.09.004.
References
[1] L. Pimpin, H. Cortez-Pinto, F. Negro, E. Corbould, J.V. Lazarus, L. Webber,
N. Sheron, Burden of liver disease in Europe: epidemiology and analysis of risk
factors to identify prevention policies, J. Hepatol. 69 (2018) 718–735.
[2] S.M. Francque, D. van der Graaﬀ, W.J. Kwanten, Non-alcoholic fatty liver disease
and cardiovascular risk: Pathophysiological mechanisms and implications, J.
Hepatol. 65 (2016) 425–443.
[3] N. Katsiki, D.P. Mikhailidis, C.S. Mantzoros, Non-alcoholic fatty liver disease and
dyslipidemia: an update, Metabolism 65 (2016) 1109–1123.
[4] S.A. Polyzos, C.S. Mantzoros, Nonalcoholic fatty future disease, Metabolism 65
(2016) 1007–1016.
[5] J. Wattacheril, D. Issa, A. Sanyal, Nonalcoholic Steatohepatitis (NASH) and Hepatic
Fibrosis: Emerging Therapies, Annu. Rev. Pharmacol. Toxicol. 58 (2018) 649–662.
[6] R. Bataller, D.A. Brenner, Liver ﬁbrosis, J. Clin. Investig. 115 (2005) 209–218.
[7] E. Seki, R.F. Schwabe, Hepatic inﬂammation and ﬁbrosis: functional links and key
pathways, Hepatology 61 (2015) 1066–1079.
[8] R. Bansal, B. Nagorniewicz, J. Prakash, Clinical advancements in the targeted
therapies against liver ﬁbrosis, Mediat. Inﬂamm. 2016 (2016) 7629724.
[9] R. Bansal, J. van Baarlen, G. Storm, J. Prakash, The interplay of the Notch signaling
Fig. 9. Increased therapeutic eﬃcacy of R406-PLGA nanoparticles in methionine and choline-deﬁcient (MCD) diet induced NASH in mice. Intrahepatic gene ex-
pression of (A) Desmin and (B) α-SMA; (C) Total serum cholesterol levels expressed in mg/dl; (D) Total serum triglyceride levels in mg/dl; Intrahepatic gene
expression of (E) uncoupling protein (UCP1); (F) PR domain containing 16 (PDRM16); (G) Peroxisome proliferator-activated receptor gamma coactivator 1-alpha
(PGC1α) and (H) c/EBPβ (CCAAT/enhancing binding protein β). Data are presented as mean+SEM. *p < 0.05, **p < 0.01 denotes signiﬁcance.
D.W. Kurniawan et al. Journal of Controlled Release 288 (2018) 227–238
237
in hepatic stellate cells and macrophages determines the fate of liver ﬁbrogenesis,
Sci. Rep. 5 (2015) 18272.
[10] B. Ozturk Akcora, G. Storm, J. Prakash, R. Bansal, Tyrosine kinase inhibitor
BIBF1120 ameliorates inﬂammation, angiogenesis and ﬁbrosis in CCl4-induced
liver ﬁbrogenesis mouse model, Sci. Rep. 7 (2017) 44545.
[11] B.O. Akcora, G. Storm, R. Bansal, Inhibition of canonical WNT signaling pathway by
beta-catenin/CBP inhibitor ICG-001 ameliorates liver ﬁbrosis in vivo through
suppression of stromal CXCL12, Biochim. Biophys. Acta 1864 (2018) 804–818.
[12] T.N. Bukong, A. Iracheta-Vellve, B. Gyongyosi, A. Ambade, D. Catalano, K. Kodys,
G. Szabo, Therapeutic Beneﬁts of Spleen Tyrosine Kinase Inhibitor Administration
on Binge Drinking-Induced Alcoholic Liver Injury, Steatosis, and Inﬂammation in
mice, Alcohol. Clin. Exp. Res. 40 (2016) 1524–1530.
[13] T.N. Bukong, A. Iracheta-Vellve, B. Saha, A. Ambade, A. Satishchandran,
B. Gyongyosi, P. Lowe, D. Catalano, K. Kodys, G. Szabo, Inhibition of spleen tyr-
osine kinase activation ameliorates inﬂammation, cell death, and steatosis in al-
coholic liver disease, Hepatology 64 (2016) 1057–1071.
[14] S.H. Shin, K.H. Lee, B.H. Kim, S. Lee, H.S. Lee, J.J. Jang, G.H. Kang,
Downregulation of spleen tyrosine kinase in hepatocellular carcinoma by promoter
CpG island hypermethylation and its potential role in carcinogenesis, Lab. Investig.
94 (2014) 1396–1405.
[15] C. Qu, D. Zheng, S. Li, Y. Liu, A. Lidofsky, J.A. Holmes, J. Chen, L. He, L. Wei,
Y. Liao, H. Yuan, Q. Jin, Z. Lin, Q. Hu, Y. Jiang, M. Tu, X. Chen, W. Li, W. Lin,
B.C. Fuchs, R.T. Chung, J. Hong, Tyrosine kinase SYK is a potential therapeutic
target for liver ﬁbrosis, Hepatology (2018), https://doi.org/10.1002/hep.29881 (in
press).
[16] A. Mocsai, J. Ruland, V.L. Tybulewicz, The SYK tyrosine kinase: a crucial player in
diverse biological functions, Nat. Rev. Immunol. 10 (2010) 387–402.
[17] T.N. Bukong, K. Kodys, G. Szabo, Human ezrin-moesin-radixin proteins modulate
hepatitis C virus infection, Hepatology 58 (2013) 1569–1579.
[18] T. Oton, L. Silva-Fernandez, J.L. Andreu, Spleen tyrosine kinase (Syk) inhibitor for
rheumatoid arthritis, N. Engl. J. Med. 364 (2011) 83.
[19] H. Okamoto, A. Kobayashi, Spleen tyrosine kinase (Syk) inhibitor for rheumatoid
arthritis, N. Engl. J. Med. 364 (2011) 83–84.
[20] E.S. Masuda, J. Schmitz, Syk inhibitors as treatment for allergic rhinitis, Pulm.
Pharmacol. Ther. 21 (2008) 461–467.
[21] M. Ulanova, F. Duta, L. Puttagunta, A.D. Schreiber, A.D. Befus, Spleen tyrosine
kinase (Syk) as a novel target for allergic asthma and rhinitis, Expert Opin. Ther.
Targets 9 (2005) 901–921.
[22] K.H. Chen, H.H. Hsu, H.Y. Yang, Y.C. Tian, Y.C. Ko, C.W. Yang, C.C. Hung,
Inhibition of spleen tyrosine kinase (syk) suppresses renal ﬁbrosis through anti-
inﬂammatory eﬀects and down regulation of the MAPK-p38 pathway, Int. J.
Biochem. Cell Biol. 74 (2016) 135–144.
[23] Y. Kulathu, G. Grothe, M. Reth, Autoinhibition and adapter function of Syk,
Immunol. Rev. 232 (2009) 286–299.
[24] M. Bartneck, K.T. Warzecha, F. Tacke, Therapeutic targeting of liver inﬂammation
and ﬁbrosis by nanomedicine, Hepatobiliary Surg Nutr 3 (2014) 364–376.
[25] H.K. Makadia, S.J. Siegel, Poly lactic-co-glycolic acid (PLGA) as biodegradable
controlled dDrug delivery carrier, Polymers (Basel) 3 (2011) 1377–1397.
[26] M. Mir, N. Ahmed, A.U. Rehman, Recent applications of PLGA based nanostructures
in drug delivery, Colloids Surf B Biointerfaces 159 (2017) 217–231.
[27] G. Sahay, D.Y. Alakhova, A.V. Kabanov, Endocytosis of nanomedicines, J. Control.
Release 145 (2010) 182–195.
[28] C. Baeck, X. Wei, M. Bartneck, V. Fech, F. Heymann, N. Gassler, K. Hittatiya,
D. Eulberg, T. Luedde, C. Trautwein, F. Tacke, Pharmacological inhibition of the
chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1)
accelerates liver ﬁbrosis regression by suppressing Ly-6C(+) macrophage inﬁltra-
tion in mice, Hepatology 59 (2014) 1060–1072.
[29] D.L. Priwitaningrum, J.G. Blonde, A. Sridhar, J. van Baarlen, W.E. Hennink,
G. Storm, S. Le Gac, J. Prakash, Tumor stroma-containing 3D spheroid arrays: a tool
to study nanoparticle penetration, J. Control. Release 244 ( (2016) 257–268.
[30] R. Bansal, J. Prakash, E. Post, L. Beljaars, D. Schuppan, K. Poelstra, Novel en-
gineered targeted interferon-gamma blocks hepatic ﬁbrogenesis in mice,
Hepatology 54 (2011) 586–596.
[31] Y.H. Lee, S.H. Kim, S.N. Kim, H.J. Kwon, J.D. Kim, J.Y. Oh, Y.S. Jung, Sex-speciﬁc
metabolic interactions between liver and adipose tissue in MCD diet-induced non-
alcoholic fatty liver disease, Oncotarget 7 (2016) 46959–46971.
[32] M. Ahrens, O. Ammerpohl, W. von Schonfels, J. Kolarova, S. Bens, T. Itzel,
A. Teufel, A. Herrmann, M. Brosch, H. Hinrichsen, W. Erhart, J. Egberts, B. Sipos,
S. Schreiber, R. Hasler, F. Stickel, T. Becker, M. Krawczak, C. Rocken, R. Siebert,
C. Schafmayer, J. Hampe, DNA methylation analysis in nonalcoholic fatty liver
disease suggests distinct disease-speciﬁc and remodeling signatures after bariatric
surgery, Cell Metab. 18 (2013) 296–302.
[33] F. Tacke, Targeting hepatic macrophages to treat liver diseases, J. Hepatol. 66
(2017) 1300–1312.
[34] Y.I. Miller, S.H. Choi, P. Wiesner, Y.S. Bae, The SYK side of TLR4: signalling me-
chanisms in response to LPS and minimally oxidized LDL, Br. J. Pharmacol. 167
(2012) 990–999.
[35] O. Gross, H. Poeck, M. Bscheider, C. Dostert, N. Hannesschlager, S. Endres,
G. Hartmann, A. Tardivel, E. Schweighoﬀer, V. Tybulewicz, A. Mocsai, J. Tschopp,
J. Ruland, Syk kinase signalling couples to the Nlrp3 inﬂammasome for anti-fungal
host defence, Nature 459 (2009) 433–436.
[36] M. Herbrink, B. Nuijen, J.H. Schellens, J.H. Beijnen, Variability in bioavailability of
small molecular tyrosine kinase inhibitors, Cancer Treat. Rev. 41 (2015) 412–422.
[37] S.J. Siegel, J.B. Kahn, K. Metzger, K.I. Winey, K. Werner, N. Dan, Eﬀect of drug type
on the degradation rate of PLGA matrices, Eur. J. Pharm. Biopharm. 64 (2006)
287–293.
[38] R.A. Drummond, S. Saijo, Y. Iwakura, G.D. Brown, The role of Syk/CARD9 coupled
C-type lectins in antifungal immunity, Eur. J. Immunol. 41 (2011) 276–281.
[39] Z. Zhang, L. He, S. Hu, Y. Wang, Q. Lai, P. Yang, Q. Yu, S. Zhang, F. Xiong,
S. Simsekyilmaz, Q. Ning, J. Li, D. Zhang, H. Zhang, X. Xiang, Z. Zhou, H. Sun,
C.Y. Wang, AAL exacerbates pro-inﬂammatory response in macrophages by reg-
ulating Mincle/Syk/Card9 signaling along with the Nlrp3 inﬂammasome assembly,
Am. J. Transl. Res. 7 (2015) 1812–1825.
[40] S.M. Rahman, J.M. Schroeder-Gloeckler, R.C. Janssen, H. Jiang, I. Qadri,
K.N. Maclean, J.E. Friedman, CCAAT/enhancing binding protein beta deletion in
mice attenuates inﬂammation, endoplasmic reticulum stress, and lipid accumula-
tion in diet-induced nonalcoholic steatohepatitis, Hepatology 45 (2007)
1108–1117.
D.W. Kurniawan et al. Journal of Controlled Release 288 (2018) 227–238
238
